{"success":true,"data":{"pressRelease":{"id":"160469","rtpr_id":"nGNX3ZZBmH-20261005","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026","author":"Globe Newswire","published_at":"2026-10-05T12:01:00.134Z","article_body":"WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq:\nARDX), a commercial-stage biopharmaceutical company focused on the development\nand commercialization of innovative medicines that meet significant unmet\nmedical needs, today announced three abstracts will be presented at the\nAmerican Society of Nephrology (ASN) Kidney Week 2026, taking place October\n21–25, 2026 in Denver, Colorado.\n\nThe poster presentations will highlight new research pertaining to the\nhyperphosphatemia treatment landscape, including real-world evidence\nevaluating the effectiveness of tenapanor with different phosphate binders,\npatient perspectives on the challenges of managing hyperphosphatemia, and an\nanalysis of the impact long-term hyperphosphatemia has on morbidity and\nmortality among patients on dialysis.\n\nPresentation Details\n\nReal-World Effectiveness of Tenapanor: Serum Phosphate Outcomes by Existing\nPhosphate Binder Use\nAuthors: Alan Fossa, Dhajanae Sylvertooth, Angelo Karaboyas, Roberto\nPecoits-Filho, Luisa L. Scott\nPoster: FR-PO0317\nPresentation Time: October 23, 2026, 10:00 am to 12:00 pm MDT\n\nPatient Perspectives on Hyperphosphatemia Management in a Contemporary\nEnd-Stage Kidney Disease Cohort: Results of an Online Survey\nAuthors: Nissreen Elfadawy, Jaime Uribarri, Janet Diaz-Martinez, Asa Renfroe,\nEmily Belcher, Luisa L. Scott\nPoster: FR-PO0324\nPresentation Time: October 23, 2026, 10:00 am to 12:00 pm MDT\n\nMorbidity and Mortality Risks Associated with Cumulative Hyperphosphatemia in\na Contemporary Cohort of US Dialysis Patients\nAuthors: Julia Scialla, Bernard Jaar, Nan Ji, Roberto Pecoits-Filho, Keith\nMcCullough, Luisa L. Scott\nPoster: FR-PO0316\nPresentation Time: October 23, 2026, 10:00 am to 12:00 pm MDT\n\nThe abstracts are available on the ASN Kidney Week 2026 website here\n(https://www.globenewswire.com/Tracker?data=NRDCAn4qHKudUm1sqHHop213BAC5QhZsl-p4x7a9bwMc02EcrVSPGRRHaA3LaNuHnW2Sr9WLUGYr1F1xDf96k4V2-smvRkN_i-Jji4EEQN_2Tg2ueh8ro4tpS5J6nnyBID_sgEw0jZnsRSIYtVZZ3Q==).\n\nIn addition to the above poster presentations, Ardelyx will host an Exhibitor\nSpotlight session titled \"Expanding Perspectives in Hyperphosphatemia\nTreatment: A Different Approach\" on Friday, October 23, 2026, at 11:00 am MDT.\nLeading nephrologist Samuel A. Kantor, MD, will present an in-depth look at\nXPHOZAH (tenapanor), a first-in-class phosphate absorption inhibitor (PAI).\nDr. Kantor will cover XPHOZAH's mechanism of action, efficacy and safety data,\nand practical guidance for its use as an add-on therapy for dialysis patients\nwho remain above guideline-established serum phosphorus targets despite\ncurrent phosphate binder treatment.\n\nAbout XPHOZAH® (tenapanor) \nXPHOZAH® (tenapanor) is the first and only phosphate absorption inhibitor\n(PAI) approved by the U.S. Food and Drug Administration to reduce serum\nphosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on\ntherapy in patients who have an inadequate response to phosphate binders or\nwho are intolerant of any dose of phosphate binder therapy. With a\ndifferentiated mechanism of action, XPHOZAH blocks phosphate absorption\nthrough the paracellular pathway, the primary pathway of phosphate absorption,\nand is administered as one tablet taken twice daily. Diarrhea was the most\ncommon side effect experienced by patients taking XPHOZAH in clinical trials.\nPlease see Important Safety Information below and click for full Prescribing\nInformation\n(https://www.globenewswire.com/Tracker?data=GJA93ulIZKatlqygIZ2ac1-kT34I9EfO4oOhxccj2yZhIOy7FUvbk2THILkl6BJgNitg_ebaLMljCmvjNPbkRdtKYDHJS2fn4z2mfAZRSrV8nuGyymmNEZX7gLxzitKodLv0m0chAcgYME85lSxnJg==).\n\nAbout Hyperphosphatemia\nHyperphosphatemia is a serious condition characterized by elevated levels of\nphosphate in the blood that affects many of the approximately 550,000 people\nin the United States with chronic kidney disease (CKD) on maintenance\ndialysis. As kidney function declines, the kidneys are unable to adequately\neliminate excess phosphate, leading to its accumulation in the blood. Elevated\nphosphate levels are associated with adverse clinical outcomes in patients\nwith CKD on dialysis. International KDIGO treatment guidelines recommend\nlowering progressively or persistently elevated serum phosphate toward the\nlaboratory-specific normal range. In adults, a commonly used reference range\nis approximately 2.5–4.5 mg/dL.\n\nIMPORTANT SAFETY INFORMATION \nCONTRAINDICATIONS\nXPHOZAH is contraindicated in:\n* Pediatric patients under 6 years of age\n* Patients with known or suspected mechanical gastrointestinal obstruction\nWARNINGS AND PRECAUTIONS\nDiarrhea \nPatients may experience severe diarrhea. Treatment with XPHOZAH should be\ndiscontinued in patients who develop severe diarrhea.\n\nMOST COMMON ADVERSE REACTIONS \nDiarrhea, which occurred in 43-53% of patients, was the only adverse reaction\nreported in at least 5% of XPHOZAH-treated patients with CKD on dialysis\nacross trials. The majority of diarrhea events in the XPHOZAH-treated patients\nwere reported to be mild-to-moderate in severity and resolved over time, or\nwith dose reduction. Diarrhea was typically reported soon after initiation but\ncould occur at any time during treatment with XPHOZAH. Severe diarrhea was\nreported in 5% of XPHOZAH-treated patients in these trials.\n\nINDICATION \nXPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in\nadults with chronic kidney disease (CKD) on dialysis as add-on therapy in\npatients who have an inadequate response to phosphate binders or who are\nintolerant of any dose of phosphate binder therapy.\n\nFor additional safety information, please see full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=GJA93ulIZKatlqygIZ2ac1-kT34I9EfO4oOhxccj2yYCYF6wS6rUnF8pO3WHlrcVMyWiC7BUyKxeODGu9F_fxJJO8F_yRHwUEcgfdXf19k84hknRROTqpB4vbfPnO2ysfz8giadk2JGbhTt-Xjlbwg==).\n\nAbout Ardelyx\n\nArdelyx is a commercial-stage biopharmaceutical company focused on the\ndevelopment and commercialization of innovative medicines that meet\nsignificant unmet medical needs. Ardelyx has two commercial products approved\nin the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The\ncompany’s pipeline includes the Phase 3 development of IBSRELA for chronic\nidiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor\nwith potential application across multiple therapeutic areas. Ardelyx works\nwith its partners to develop and commercialize its products outside of the\nUnited States. For more information, please visit https://ardelyx.com/ and\nconnect with us on X (formerly known as Twitter)\n(https://www.globenewswire.com/Tracker?data=kp5dsdaQAy2rQf8hhIX4QpJKAoasg5Fc3pGyDUqaj0GE8D6XGNJ3wHCY0eIHNbfFI6xU6sc17Skp0_DxRjhwlLG7tHIW52JC-MtOCkFW7lAyHoPN-NS-qYVcat1AzyGp),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=mmzq-JxqQISowhdqbai0oQxfp1y5Z0FgabUJWoaRqcGTE2mfl0YPb4dZOEPvQG5CHf9dw4jIXdycm1G4F3uOZwdAqSgitrYbAOpycvirtwiXvCSqB9K6RSOaR06tNRRS)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=TQobkZQ8BgUStn3b4EwCPYaPusnQBhIeJTZYKc-VeBMwmPFagEny_K4w4OX5yqZRztlVY86Hf5PRmt2OWlnYMhdQ3UdkYIbA_kOzxcb6nqI=).\n\nForward Looking Statements\n\nTo the extent that statements contained in this press release are not\ndescriptions of historical facts regarding Ardelyx, they are forward-looking\nstatements reflecting the current beliefs and expectations of management made\npursuant to the safe harbor of the Private Securities Litigation Reform Act of\n1995, including Ardelyx’s current expectations regarding: the anticipated\npresentation of data at ASN Kidney Week 2026, including the timing and content\nof the poster presentations and the Exhibitor Spotlight session. Such\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that are in some cases beyond our control, that could cause\nactual outcomes or results to differ materially from those expressed or\nimplied by the forward-looking statements. Such risks and uncertainties\ninclude, among others, uncertainties associated with the development of,\nregulatory process for, and commercialization of drugs in the U.S. and\ninternationally, and the risk that real-world, post hoc, survey or other\nanalyses may not be indicative of future results or may be interpreted\ndifferently by others. Ardelyx undertakes no obligation to update or revise\nany forward-looking statements. For a further description of the risks and\nuncertainties that could cause actual results to differ from those expressed\nin these forward-looking statements, as well as risks relating to Ardelyx’s\nbusiness in general, please refer to Ardelyx's Quarterly Report on Form 10-Q\nfiled with the Securities and Exchange Commission on August 6, 2026, and its\nfuture current and periodic reports to be filed with the Securities and\nExchange Commission.\n\nInvestor Contact:\nLisa Caperelli\nSVP, Investor Relations & Corporate Communications\nlcaperelli@ardelyx.com\n\nMedia Contact:\nLindsey Manuel\nAssociate Director, Corporate Communications\nlmanuel@ardelyx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3ZZBmH-20261005","title":"Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026","author":"Globe Newswire","ticker":"ARDX","created":"2026-10-05T12:01:00.134Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq:\nARDX), a commercial-stage biopharmaceutical company focused on the development\nand commercialization of innovative medicines that meet significant unmet\nmedical needs, today announced three abstracts will be presented at the\nAmerican Society of Nephrology (ASN) Kidney Week 2026, taking place October\n21–25, 2026 in Denver, Colorado.\n\nThe poster presentations will highlight new research pertaining to the\nhyperphosphatemia treatment landscape, including real-world evidence\nevaluating the effectiveness of tenapanor with different phosphate binders,\npatient perspectives on the challenges of managing hyperphosphatemia, and an\nanalysis of the impact long-term hyperphosphatemia has on morbidity and\nmortality among patients on dialysis.\n\nPresentation Details\n\nReal-World Effectiveness of Tenapanor: Serum Phosphate Outcomes by Existing\nPhosphate Binder Use\nAuthors: Alan Fossa, Dhajanae Sylvertooth, Angelo Karaboyas, Roberto\nPecoits-Filho, Luisa L. Scott\nPoster: FR-PO0317\nPresentation Time: October 23, 2026, 10:00 am to 12:00 pm MDT\n\nPatient Perspectives on Hyperphosphatemia Management in a Contemporary\nEnd-Stage Kidney Disease Cohort: Results of an Online Survey\nAuthors: Nissreen Elfadawy, Jaime Uribarri, Janet Diaz-Martinez, Asa Renfroe,\nEmily Belcher, Luisa L. Scott\nPoster: FR-PO0324\nPresentation Time: October 23, 2026, 10:00 am to 12:00 pm MDT\n\nMorbidity and Mortality Risks Associated with Cumulative Hyperphosphatemia in\na Contemporary Cohort of US Dialysis Patients\nAuthors: Julia Scialla, Bernard Jaar, Nan Ji, Roberto Pecoits-Filho, Keith\nMcCullough, Luisa L. Scott\nPoster: FR-PO0316\nPresentation Time: October 23, 2026, 10:00 am to 12:00 pm MDT\n\nThe abstracts are available on the ASN Kidney Week 2026 website here\n(https://www.globenewswire.com/Tracker?data=NRDCAn4qHKudUm1sqHHop213BAC5QhZsl-p4x7a9bwMc02EcrVSPGRRHaA3LaNuHnW2Sr9WLUGYr1F1xDf96k4V2-smvRkN_i-Jji4EEQN_2Tg2ueh8ro4tpS5J6nnyBID_sgEw0jZnsRSIYtVZZ3Q==).\n\nIn addition to the above poster presentations, Ardelyx will host an Exhibitor\nSpotlight session titled \"Expanding Perspectives in Hyperphosphatemia\nTreatment: A Different Approach\" on Friday, October 23, 2026, at 11:00 am MDT.\nLeading nephrologist Samuel A. Kantor, MD, will present an in-depth look at\nXPHOZAH (tenapanor), a first-in-class phosphate absorption inhibitor (PAI).\nDr. Kantor will cover XPHOZAH's mechanism of action, efficacy and safety data,\nand practical guidance for its use as an add-on therapy for dialysis patients\nwho remain above guideline-established serum phosphorus targets despite\ncurrent phosphate binder treatment.\n\nAbout XPHOZAH® (tenapanor) \nXPHOZAH® (tenapanor) is the first and only phosphate absorption inhibitor\n(PAI) approved by the U.S. Food and Drug Administration to reduce serum\nphosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on\ntherapy in patients who have an inadequate response to phosphate binders or\nwho are intolerant of any dose of phosphate binder therapy. With a\ndifferentiated mechanism of action, XPHOZAH blocks phosphate absorption\nthrough the paracellular pathway, the primary pathway of phosphate absorption,\nand is administered as one tablet taken twice daily. Diarrhea was the most\ncommon side effect experienced by patients taking XPHOZAH in clinical trials.\nPlease see Important Safety Information below and click for full Prescribing\nInformation\n(https://www.globenewswire.com/Tracker?data=GJA93ulIZKatlqygIZ2ac1-kT34I9EfO4oOhxccj2yZhIOy7FUvbk2THILkl6BJgNitg_ebaLMljCmvjNPbkRdtKYDHJS2fn4z2mfAZRSrV8nuGyymmNEZX7gLxzitKodLv0m0chAcgYME85lSxnJg==).\n\nAbout Hyperphosphatemia\nHyperphosphatemia is a serious condition characterized by elevated levels of\nphosphate in the blood that affects many of the approximately 550,000 people\nin the United States with chronic kidney disease (CKD) on maintenance\ndialysis. As kidney function declines, the kidneys are unable to adequately\neliminate excess phosphate, leading to its accumulation in the blood. Elevated\nphosphate levels are associated with adverse clinical outcomes in patients\nwith CKD on dialysis. International KDIGO treatment guidelines recommend\nlowering progressively or persistently elevated serum phosphate toward the\nlaboratory-specific normal range. In adults, a commonly used reference range\nis approximately 2.5–4.5 mg/dL.\n\nIMPORTANT SAFETY INFORMATION \nCONTRAINDICATIONS\nXPHOZAH is contraindicated in:\n* Pediatric patients under 6 years of age\n* Patients with known or suspected mechanical gastrointestinal obstruction\nWARNINGS AND PRECAUTIONS\nDiarrhea \nPatients may experience severe diarrhea. Treatment with XPHOZAH should be\ndiscontinued in patients who develop severe diarrhea.\n\nMOST COMMON ADVERSE REACTIONS \nDiarrhea, which occurred in 43-53% of patients, was the only adverse reaction\nreported in at least 5% of XPHOZAH-treated patients with CKD on dialysis\nacross trials. The majority of diarrhea events in the XPHOZAH-treated patients\nwere reported to be mild-to-moderate in severity and resolved over time, or\nwith dose reduction. Diarrhea was typically reported soon after initiation but\ncould occur at any time during treatment with XPHOZAH. Severe diarrhea was\nreported in 5% of XPHOZAH-treated patients in these trials.\n\nINDICATION \nXPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in\nadults with chronic kidney disease (CKD) on dialysis as add-on therapy in\npatients who have an inadequate response to phosphate binders or who are\nintolerant of any dose of phosphate binder therapy.\n\nFor additional safety information, please see full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=GJA93ulIZKatlqygIZ2ac1-kT34I9EfO4oOhxccj2yYCYF6wS6rUnF8pO3WHlrcVMyWiC7BUyKxeODGu9F_fxJJO8F_yRHwUEcgfdXf19k84hknRROTqpB4vbfPnO2ysfz8giadk2JGbhTt-Xjlbwg==).\n\nAbout Ardelyx\n\nArdelyx is a commercial-stage biopharmaceutical company focused on the\ndevelopment and commercialization of innovative medicines that meet\nsignificant unmet medical needs. Ardelyx has two commercial products approved\nin the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The\ncompany’s pipeline includes the Phase 3 development of IBSRELA for chronic\nidiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor\nwith potential application across multiple therapeutic areas. Ardelyx works\nwith its partners to develop and commercialize its products outside of the\nUnited States. For more information, please visit https://ardelyx.com/ and\nconnect with us on X (formerly known as Twitter)\n(https://www.globenewswire.com/Tracker?data=kp5dsdaQAy2rQf8hhIX4QpJKAoasg5Fc3pGyDUqaj0GE8D6XGNJ3wHCY0eIHNbfFI6xU6sc17Skp0_DxRjhwlLG7tHIW52JC-MtOCkFW7lAyHoPN-NS-qYVcat1AzyGp),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=mmzq-JxqQISowhdqbai0oQxfp1y5Z0FgabUJWoaRqcGTE2mfl0YPb4dZOEPvQG5CHf9dw4jIXdycm1G4F3uOZwdAqSgitrYbAOpycvirtwiXvCSqB9K6RSOaR06tNRRS)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=TQobkZQ8BgUStn3b4EwCPYaPusnQBhIeJTZYKc-VeBMwmPFagEny_K4w4OX5yqZRztlVY86Hf5PRmt2OWlnYMhdQ3UdkYIbA_kOzxcb6nqI=).\n\nForward Looking Statements\n\nTo the extent that statements contained in this press release are not\ndescriptions of historical facts regarding Ardelyx, they are forward-looking\nstatements reflecting the current beliefs and expectations of management made\npursuant to the safe harbor of the Private Securities Litigation Reform Act of\n1995, including Ardelyx’s current expectations regarding: the anticipated\npresentation of data at ASN Kidney Week 2026, including the timing and content\nof the poster presentations and the Exhibitor Spotlight session. Such\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that are in some cases beyond our control, that could cause\nactual outcomes or results to differ materially from those expressed or\nimplied by the forward-looking statements. Such risks and uncertainties\ninclude, among others, uncertainties associated with the development of,\nregulatory process for, and commercialization of drugs in the U.S. and\ninternationally, and the risk that real-world, post hoc, survey or other\nanalyses may not be indicative of future results or may be interpreted\ndifferently by others. Ardelyx undertakes no obligation to update or revise\nany forward-looking statements. For a further description of the risks and\nuncertainties that could cause actual results to differ from those expressed\nin these forward-looking statements, as well as risks relating to Ardelyx’s\nbusiness in general, please refer to Ardelyx's Quarterly Report on Form 10-Q\nfiled with the Securities and Exchange Commission on August 6, 2026, and its\nfuture current and periodic reports to be filed with the Securities and\nExchange Commission.\n\nInvestor Contact:\nLisa Caperelli\nSVP, Investor Relations & Corporate Communications\nlcaperelli@ardelyx.com\n\nMedia Contact:\nLindsey Manuel\nAssociate Director, Corporate Communications\nlmanuel@ardelyx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-05T12:01:00.256898658Z","server_sent_at_ms":1791201660256},"received_at":"2026-10-05T12:01:00.390Z","source_url":null},"analysis":{"id":"149032","press_release_id":"160469","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, October 21-25 in Denver, covering real-world effectiveness of tenapanor, patient perspectives, and hyperphosphatemia's impact on dialysis patient outcomes.\n\nThe company will also host an Exhibitor Spotlight on October 23 featuring nephrologist Samuel A. Kantor presenting an in-depth look at XPHOZAH, its first-in-class phosphate absorption inhibitor approved as add-on therapy for dialysis patients.\n\nThe release is a scheduling announcement with no new clinical or financial results; data presentation could modestly support XPHOZAH commercial messaging but carries no near-term catalyst.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference presentation announcement -- watch for actual real-world tenapanor data at Kidney Week on October 23."},"keyFigures":{"drugName":"XPHOZAH (tenapanor)","customDimensions":{"severe_diarrhea_rate":"5%","dialysis_population_us":"approximately 550,000","diarrhea_adverse_reaction_rate":"43-53%"}},"namedEntities":{"people":[{"name":"Samuel A. Kantor","role":"nephrologist presenting Exhibitor Spotlight"},{"name":"Luisa L. Scott","role":"abstract author"},{"name":"Roberto Pecoits-Filho","role":"abstract author"},{"name":"Keith McCullough","role":"abstract author"}],"products":["XPHOZAH (tenapanor)","IBSRELA (tenapanor)","RDX10531"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"filer"},{"name":"American Society of Nephrology","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference-announcement press release listing upcoming poster presentations and an exhibitor spotlight for XPHOZAH. No new clinical results, financial data, or regulatory action disclosed."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"conference announcement, no new data","issuerAuthored":true,"retailFavoriteBoost":false}},"event_type":"operations_update","event_type_secondary":["product_launch"],"sentiment":"neutral","material_impact_score":1,"narrative":"Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, October 21-25 in Denver, covering real-world effectiveness of tenapanor, patient perspectives, and hyperphosphatemia's impact on dialysis patient outcomes.\n\nThe company will also host an Exhibitor Spotlight on October 23 featuring nephrologist Samuel A. Kantor presenting an in-depth look at XPHOZAH, its first-in-class phosphate absorption inhibitor approved as add-on therapy for dialysis patients.\n\nThe release is a scheduling announcement with no new clinical or financial results; data presentation could modestly support XPHOZAH commercial messaging but carries no near-term catalyst.","key_figures":{"drugName":"XPHOZAH (tenapanor)","customDimensions":{"severe_diarrhea_rate":"5%","dialysis_population_us":"approximately 550,000","diarrhea_adverse_reaction_rate":"43-53%"}},"named_entities":{"people":[{"name":"Samuel A. Kantor","role":"nephrologist presenting Exhibitor Spotlight"},{"name":"Luisa L. Scott","role":"abstract author"},{"name":"Roberto Pecoits-Filho","role":"abstract author"},{"name":"Keith McCullough","role":"abstract author"}],"products":["XPHOZAH (tenapanor)","IBSRELA (tenapanor)","RDX10531"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"filer"},{"name":"American Society of Nephrology","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T12:01:05.249Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"conference announcement, no new data","issuerAuthored":true,"retailFavoriteBoost":false}},"durationMs":4837,"modelName":"glm-5.3-flashx"}}